Thyssen, J.P., Vestergaard, C., Barbarot, S. et al. (32 more authors) (2021) European Task Force on Atopic Dermatitis (ETFAD): position on vaccination of adult patients with atopic dermatitis against COVID‐19 (SARS‐CoV‐2) being treated with systemic medication and biologics. Journal of the European Academy of Dermatology and Venereology, 35 (5). e308-e311. ISSN 0926-9959
Abstract
The coronavirus disease 2019 (COVID‐19) pandemic is caused by rapid spread of different strains of the severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2). The severity of infection ranges from mild, or even asymptomatic, to very severe. Signs and symptoms include fatigue, fever, exanthemas, upper respiratory illness, loss of smell and taste, pneumonia, severe acute respiratory syndrome, and multi‐organ failure. Risk factors for a severe or lethal course include age, male gender, obesity, diabetes, cardiovascular disease, and immune suppression1.
Metadata
Item Type: | Article |
---|---|
Authors/Creators: |
|
Copyright, Publisher and Additional Information: | © 2021 European Academy of Dermatology and Venereology. This is an author-produced version of a paper subsequently published in Journal of the European Academy of Dermatology and Venereology. Uploaded in accordance with the publisher's self-archiving policy. |
Keywords: | atopic dermatitis; covid‐19; vaccine; vaccination |
Dates: |
|
Institution: | The University of Sheffield |
Academic Units: | The University of Sheffield > Sheffield Teaching Hospitals |
Depositing User: | Symplectic Sheffield |
Date Deposited: | 24 Feb 2021 16:08 |
Last Modified: | 17 Feb 2022 09:56 |
Status: | Published |
Publisher: | Wiley |
Refereed: | Yes |
Identification Number: | 10.1111/jdv.17167 |
Related URLs: | |
Open Archives Initiative ID (OAI ID): | oai:eprints.whiterose.ac.uk:171529 |